Table 2.

Demographics of the matched cohorts of the LEVO-D and REGALAD studies. BMI: body mass index. LVEF: left ventricular ejection fraction. LVEDD: left ventricular end-diastolic dimension. RV: right ventricle. MR: mitral regurgitation. TR: tricuspid regurgitation. sPAP: systolic pulmonary artery pressure. HR: heart rate. MDRD4. modification of diet in renal disease 4. NT-ProBNP: N-terminal pro-brain natriuretic peptide. ACE-i: angiotensin-converting-enzyme inhibitors. ARB: angiotensin receptor antagonists. ARNI: angiotensin receptor neprilysin inhibitors. MRA: mineralocorticoid receptor antagonist. ICD: implantable cardioverter defibrillator. CRT: cardiac resynchronization therapy. NYHA: New York Heart Association. OAC: oral anticoagulation.

	LEVO-D (53)	REGALAD (53)	p Value
Age (years, mean)	69.6 ± 8.9	68.4 ± 4.8	0.39
Sex (male)	73.6%	77.4%	0.87
BMI (mean)	25.8 ± 3.9	26.9 ± 3.8	0.16
Hypertension	64.2%	66%	0.84
Diabetes	52.8%	52.8%	0.99
Atrial tachyarrhythmias	39.6%	35.8%	0.84
IHD	60.4%	60.4%	0.99
LVEF (%, mean)	24.1%	23.5%	0.66
LVEDD (mm, mean)	66.5 ± 5.7	67.4 ± 10.8	0.60
RV dysfunction	54.7%	54.7%	0.99
MR III-IV	52.8%	56.6%	0.85
TR III-IV	37.7%	37.7%	0.99
SPAP (mmHg, mean)	49.2 ± 10.4	47.5 ± 13.3	0.47
SBP (mmHg, mean)	104.3 ± 16.6	103.2 ± 16.5	0.75
HR (bpm, mean)	75.9 ± 13.2	75.3 ± 12.7	0.81
MDRD4 (mL/min, mean)	53.7 ± 29.4	52 ± 23.6	0.67
NT-ProBNP (pg/mL, mean)	7910 ± 7000	7157 ± 6317	0.56
Hemoglobin (gr/dL, mean)	11.9 ± 1.7	11.9 ± 2.1	0.87
ACE-i/ARB/ARNI	62.2%	68%	0.68
Beta-blockers	67.9%	67.9%	0.99
ARM	69.7%	69.8%	0.99
Amiodarone	28.3%	30.2%	0.98
OAC	50.9%	56.6%	0.69
Digoxin	18.9%	20.8%	0.99
Furosemide	94.3%	94.3%	0.99
ICD	67.9%	71.7%	0.83
CRT	41.5%	47.2%	0.70
NYHA IV	41.5%	39.6%	0.99
3 or more HF admissions	20.8%	24.5%	0.82